## Dariusz T Å **L**adowski

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3570256/publications.pdf

Version: 2024-02-01

28 papers 1,350 citations

567281 15 h-index 25 g-index

29 all docs 29 docs citations

29 times ranked 1436 citing authors

#	Article	IF	CITATIONS
1	Mosaic <i>IL6ST</i> variant inducing constitutive GP130 cytokine receptor signaling as a cause of neonatal onset immunodeficiency with autoinflammation and dysmorphy. Human Molecular Genetics, 2021, 30, 226-233.	2.9	8
2	Variable degree of mosaicism for tetrasomy 18p in phenotypically discordant monozygotic twins—Diagnostic implications. Molecular Genetics & Enomic Medicine, 2021, 9, e1526.	1.2	7
3	The Three Rs and Alternatives in the Visegr $ ilde{A}_i$ d (V4) Countries. , 2019, , 59-70.		O
4	Dominant <i>ELOVL1</i> mutation causes neurological disorder with ichthyotic keratoderma, spasticity, hypomyelination and dysmorphic features. Journal of Medical Genetics, 2018, 55, 408-414.	3.2	41
5	Reconstruction method for extended depth-of-field optical diffraction tomography. Methods, 2018, 136, 40-49.	3.8	21
6	Cell and Gene Therapies: European View on Challenges in Translation and How to Address Them. Frontiers in Medicine, 2018, 5, 158.	2.6	17
7	Clinical Development and Commercialization of Advanced Therapy Medicinal Products in the European Union: How Are the Product Pipeline and Regulatory Framework Evolving?. Human Gene Therapy Clinical Development, 2017, 28, 126-135.	3.1	44
8	Manufacturing, characterization and control of cell-based medicinal products: challenging paradigms toward commercial use. Regenerative Medicine, 2015, 10, 65-78.	1.7	40
9	Synthesis and anticancer activity of 7-hydroxycoumarinyl gallates. Pharmacological Reports, 2015, 67, 236-244.	3.3	11
10	Experimental immunology Xenotransplantation of human cultured parathyroid progenitor cells into mouse peritoneum does not induce rejection reaction. Central-European Journal of Immunology, 2014, 3, 279-284.	1.2	3
11	The expression of membranous complement inhibitors CD46, CD55 and CD59 in the primary and metastatic colon cancer cell lines derived from the same patient. Central-European Journal of Immunology, 2013, 4, 549-555.	1.2	О
12	Comparison of the expression of complement regulatory proteins CD46, CD55 and CD59 in primary colon cancer and synchronous/metachronous liver metastases. Central-European Journal of Immunology, 2013, 4, 543-548.	1.2	0
13	Fluvastatin increases tyrosinase synthesis induced by $\hat{I}\pm$ -melanocyte-stimulating hormone in B16F10 melanoma cells. Pharmacological Reports, 2010, 62, 164-169.	3.3	12
14	The possible role of factor H in colon cancer resistance to complement attack. International Journal of Cancer, 2008, 122, 2030-2037.	5.1	44
15	Barriers to Validation. ATLA Alternatives To Laboratory Animals, 2008, 36, 459-464.	1.0	7
16	An Evaluation of Sterilisation Processes. ATLA Alternatives To Laboratory Animals, 2008, 36, 585-590.	1.0	1
17	Allotransplantation of Cultured Parathyroid Progenitor Cells Without Immunosuppression: Clinical Results. Transplantation, 2007, 83, 734-740.	1.0	51
18	Culture of the primary corneal epithelium as a potential component of test batteries for eye irritancy testing. Toxicology in Vitro, 2005, 19, 875-878.	2.4	7

#	Article	IF	CITATIONS
19	ESTIV questionnaire on the acquisition and use of primary human cells and tissue in toxicology. Toxicology in Vitro, 2005, 19, 1009-1013.	2.4	3
20	ECVAM'S Activities in the EU Candidate Countries. ATLA Alternatives To Laboratory Animals, 2002, 30, 203-205.	1.0	0
21	The Establishment of Human Research Tissue Banking in the UK and Several Western European Countries. ATLA Alternatives To Laboratory Animals, 2001, 29, 125-134.	1.0	28
22	In vitro reconstruction of full thickness human skin on a composite collagen material. Cell and Tissue Banking, 2001, 2, 165-171.	1.1	15
23	Preserved tissue allografts in reconstructive surgery. Cell and Tissue Banking, 2001, 2, 103-112.	1.1	33
24	The International EU/COLIPA In Vitro Phototoxicity Validation Study: Results of Phase II (Blind Trial). Part 1: The 3T3 NRU Phototoxicity Test. Toxicology in Vitro, 1998, 12, 305-327.	2.4	251
25	The Availability of Human Tissue for Biomedical Research: The Report and Recommendations of the ECVAM Workshop 32. ATLA Alternatives To Laboratory Animals, 1998, 26, 763-77.	1.0	27
26	Practical Aspects of the Validation of Toxicity Test Procedures. ATLA Alternatives To Laboratory Animals, 1995, 23, 129-146.	1.0	240
27	<i>In Vitro</i> Phototoxicity Testing. ATLA Alternatives To Laboratory Animals, 1994, 22, 314-348.	1.0	86
28	An improved MIT assay. Journal of Immunological Methods, 1993, 157, 203-207.	1.4	352